Dr. Freed is the Chief Science Officer and Co-Founder of RheumaGen. He is also the Executive Director of ClinImmune Cell & Gene Therapy, Professor of Medicine and Immunology at the University of Colorado School of Medicine, and the inventor of RheumaGen’s breakthrough HLA gene editing technology. Dr. Freed is a world class expert in the HLA gene, with greater than 40 years of experience and more than 100 publications in the areas of immunogenetics, biotherapeutics, histocompatibility, transplantation, and stem cell banking.

Dr. Freed spent most of his early career at Albany Medical College, where he received his PhD in 1990 and was an Assistant Instructor in the Department of Surgery (1984-1990), Assistant Professor of Surgery (1990-1996), Immunology and Molecular Genetics (1991-1996), Pharmacology (1992-1997), and Associate Professor of Surgery (1996-1997), and Pathology and Laboratory Medicine (1996-1997) . Additionally, he was the Supervisor (1981-1991) and then Director (1992-1997) of the Transplantation Immunology Laboratory at Albany Medical College. In 1997 he moved to Denver and the University of Colorado, where he was Director of the University of Colorado Clinical Immunology and Histocompatibility Lab (1997-2001), and Associate Professor of Medicine and Immunology (1997-2003). In 2001, he became the Executive Director of ClinImmune Cell & Gene Therapy, and in 2003 he became Professor of Medicine and Immunology at the University of Colorado School of Medicine. From 1999-2003, he was also the Consulting Director of the Kunming Medical College HLA Laboratory in Kunming, P.R., China. He has been a Member of the Immunological Devices Panel for the U.S. Food and Drug Administration since 2008. Dr. Freed has been the Principal Investigator (PI) or co-investigator on grant projects that have received more than $12 million in funding.

 For Dr. Freed’s full CV and complete list of publications, click here.